Addressing adolescent substance use with a public health prevention framework: the case for harm reduction

References

• Committee on the Neurobiological and Socio-behavioral Science of Adolescent Development and Its Applications Board on Children, Youth, and Families, Division of Behavioral and Social Sciences and Education, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. The promise of adolescence: realizing opportunity for all youth. Bonnie RJ, Backes EP, editors. Washington (DC): National Academies Press; 2019.
   Google Scholar
• Jordan CJ, Andersen SL. Sensitive periods of substance abuse: early risk for the transition to dependence. Dev Cogn Neurosci. 2017;25:29–44.
   PubMed Web of Science ®Google Scholar
• Hingson RW, Heeren T, Winter MR. Age at drinking onset and alcohol dependence: age at onset, duration, and severity. Arch Pediatr Adolesc Med. 2006;160(7):739–746.
   PubMed Web of Science ®Google Scholar
• McCabe SE, Schulenberg JE, Schepis TS, et al. Longitudinal analysis of substance use disorder symptom severity at age 18 years and substance use disorder in adulthood. JAMA Netw Open. 2022;5(4):e225324.
   PubMed Web of Science ®Google Scholar
• Shrier LA, Harris SK, Sternberg M, et al. Associations of depression, self-esteem, and substance use with sexual risk among adolescents. Prev Med. 2001;33(3):179–189.
   PubMed Web of Science ®Google Scholar
• Toumbourou J, Stockwell T, Neighbors C, et al. Interventions to reduce harm associated with adolescent substance use. Lancet. 2007;369(9570):1391–1401.
   PubMed Web of Science ®Google Scholar
• The 2021 Monitoring the Future data tables available online from the University of Michigan. [cited 2021 Dec 23]. Available from: http://monitoringthefuture.org/data/21data/Alcohol/Alcohol_jsFigures.htm.
   Google Scholar
• Levy S, Campbell MD, Shea CL, et al. Trends in substance nonuse by high school seniors: 1975–2018. Pediatrics. 2020;146(6):e2020007187.
   PubMed Web of Science ®Google Scholar
• Miech RA, Johnston LD, O’Malley PM, et al. 2021. Monitoring the future national survey results on drug use, 1975–2020: volume I, secondary school students. Ann Arbor: Institute for Social Research, The University of Michigan. Available from: http://monitoringthefuture.org/pubs.html#monographs.
   Google Scholar
• Jang JB, Patrick ME, Keyes KM, et al. Frequent binge drinking among US adolescents, 1991 to 2015. Pediatrics. 2017;139(6):e20164023.
   PubMed Web of Science ®Google Scholar
• Kidd JD, Jackman KB, Wolff M, et al. Risk and protective factors for substance use among sexual and gender minority youth: a scoping review. Curr Addict Rep. 2018;5(2):158–173.
   PubMedGoogle Scholar
• Day JK, Fish JN, Perez-Brumer A, et al. Transgender youth substance use disparities: results from a population-based sample. J Adolesc Health. 2017;61(6):729–735.
   PubMed Web of Science ®Google Scholar
• Committee on Applying Lessons of Optimal Adolescent Health to Improve Behavioral Outcomes for Youth Board on Children, Youth, and Families, Division of Behavioral and Social Sciences and Education, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Promoting positive adolescent health behaviors and outcomes: thriving in the 21st century. Graham R, Kahn NF, editors. Washington (DC): National Academies Press; 2020.
   Google Scholar
• National Institute on Drug Abuse (NIDA). Universal programs. National Institute on Drug Abuse. [cited 2021 Dec 16]. https://www.drugabuse.gov/publications/preventing-drug-use-among-children-adolescents/chapter-4-examples-research-based-drug-abuse-prevention-programs/universal-programs
   Google Scholar
• Tremblay M, Baydala L, Khan M, et al. Primary substance use prevention programs for children and youth: a systematic review. Pediatrics. 2020;146(3):e20192747.
   PubMed Web of Science ®Google Scholar
• Levy SJ, Williams JF, Ryan SA, et al. Substance use screening, brief intervention, and referral to treatment. Pediatrics. 2016;138(1):e20161211.
   PubMedGoogle Scholar
• What is harm reduction? | Harm Reduction International. [cited 2021 Dec 16]. https://www.hri.global/what-is-harm-reduction.
   Google Scholar
• Lim JK, Earlywine JJ, Bagley SM, et al. Polysubstance involvement in opioid overdose deaths in adolescents and young adults, 1999–2018. JAMA Pediatr. 2021;175(2):194–196.
   PubMed Web of Science ®Google Scholar
• Benthin A, Slovic P, Severson H. A psychometric study of adolescent risk perception. J Adolesc. 1993;16(2):153–168.
   PubMed Web of Science ®Google Scholar
• Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3(8):760–773.
   PubMed Web of Science ®Google Scholar
• Information NC for B, Pike USNL of M, 8600 R, et al. Harm reduction: an approach to reducing risky health behaviours in adolescents. Paediatr Child Health. 2008;13(1):53.
   PubMed Web of Science ®Google Scholar
• Tanner MR, Miele P, Carter W, et al. Preexposure prophylaxis for prevention of HIV acquisition among adolescents: clinical considerations, 2020. MMWR Recomm Rep. 2020;69(3):1–12.
   PubMed Web of Science ®Google Scholar
• Jenkins EK, Slemon A, Haines-Saah RJ. Developing harm reduction in the context of youth substance use: insights from a multi-site qualitative analysis of young people’s harm minimization strategies. Harm Reduct J. 2017;14(1):53.
   PubMed Web of Science ®Google Scholar
• 2012 Surgeon General’s Report | Smoking & Tobacco Use | CDC. [updated 2021 June 2; cited 2021 Dec 16]. http://www.cdc.gov/tobacco/data_statistics/sgr/2012/index.htm.
   Google Scholar
• Trends in Tobacco Use Among Youth. [updated 2022 April 12; cited 2022 May 2]. http://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/trends-in-tobacco-use-among-youth.html.
   Google Scholar
• Godley SH, Meyers RJ, Smith JE, et al. The adolescent community reinforcement approach for adolescent cannabis users, Cannabis Youth Treatment (CYT) Series, Volume 4. DHHS Pub. No. 01–3489. Rockville (MD): Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 2001. p. 203.
   Google Scholar
• Chaiton M, Diemert L, Cohen JE, et al. Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers. BMJ Open. 2016;6(6):e011045.
   PubMed Web of Science ®Google Scholar
• Chadi N, Li G, Cerda N, et al. Depressive symptoms and suicidality in adolescents using e-Cigarettes and marijuana: a secondary data analysis from the youth risk behavior survey. J Addict Med. 2019;13(5):362–365.
   PubMed Web of Science ®Google Scholar
• Stanton A, Grimshaw G. Tobacco cessation interventions for young people. Cochrane Database Syst Rev. 2013;(8):CD003289. Update in: Cochrane Database Syst Rev. 2017 Nov 17;11:CD003289. PMID: 23975659.
   Google Scholar
• Roll JM. Assessing the feasibility of using contingency management to modify cigarette smoking by adolescents. J Appl Behav Anal. 2005;38(4):463–467.
   PubMed Web of Science ®Google Scholar
• Reynolds B, Harris M, Slone SA, et al. A feasibility study of home-based contingency management with adolescent smokers of rural appalachia. Exp Clin Psychopharmacol. 2015;23(6):486–493.
   PubMed Web of Science ®Google Scholar
• Harvanko A, Slone S, Shelton B, et al. Web-based contingency management for adolescent tobacco smokers: a clinical trial. Nicotine Tob Res. 2020;22(3):332–338.
   PubMed Web of Science ®Google Scholar
• Selph S, Patnode C, Bailey SR, et al. Primary care–relevant interventions for tobacco and nicotine use prevention and cessation in children and adolescents: Updated evidence report and systematic review for the US preventive services task force. JAMA. 2020;323(16):1599–1608.
   PubMed Web of Science ®Google Scholar
• Home | Smokefree Teen. [cited 2021 Dec 16]. https://teen.smokefree.gov/.
   Google Scholar
• Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Potency of Cannabis Samples Seized by the Drug Enforcement Administration (DEA), Percent Averages from 1995-2019. Source: Potency Monitoring Program, Quarterly Report # 146, NIDA Contract Number: N01DA-15-7793.
   Google Scholar
• National Institute on Drug Abuse. Marijuana concentrates drugfacts. National Institute on Drug Abuse. [updated 2020 June 25; cited 2021 Dec 16]. https://www.drugabuse.gov/publications/drugfacts/marijuana-concentrates.
   Google Scholar
• Arterberry BJ, Padovano HT, Foster KT, et al. Higher average potency across the United States is associated with progression to first cannabis use disorder symptom. Drug Alcohol Depend. 2019;195:186–192.
   PubMed Web of Science ®Google Scholar
• Noble MJ, Hedberg K, Hendrickson RG. Acute cannabis toxicity. Clin Toxicol Phila Pa. 2019;57(8):735–742.
   PubMed Web of Science ®Google Scholar
• Budney AJ, Moore BA, Vandrey RG, et al. The time course and significance of cannabis withdrawal. J Abnorm Psychol. 2003;112(3):393–402.
   PubMed Web of Science ®Google Scholar
• Livne O, Shmulewitz D, Lev-Ran S, et al. DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. Drug Alcohol Depend. 2019;195:170–177.
   PubMed Web of Science ®Google Scholar
• Know the Risks: E-cigarettes & Young People | U.S. Surgeon General’s Report. [cited 2021 Dec 16]. https://e-cigarettes.surgeongeneral.gov/.
   Google Scholar
• Fadus MC, Smith TT, Squeglia LM. The rise of e-cigarettes, pod mod devices, and JUUL among youth: factors influencing use, health implications, and downstream effects. Drug Alcohol Depend. 2019;201:85–93.
   PubMed Web of Science ®Google Scholar
• Hammond D, Wadsworth E, Reid JL, et al. Prevalence and modes of cannabis use among youth in Canada, England, and the US, 2017 to 2019. Drug Alcohol Depend. 2021;219:108505.
   PubMed Web of Science ®Google Scholar
• Overbeek DL, Kass AP, Chiel LE, et al. A review of toxic effects of electronic cigarettes/vaping in adolescents and young adults. Crit Rev Toxicol. 2020;50(6):531–538.
   PubMed Web of Science ®Google Scholar
• East K, Hitchman SC, Bakolis I, et al. The association between smoking and electronic cigarette use in a cohort of young people. J Adolesc Health. 2018;62(5):539–547.
   PubMed Web of Science ®Google Scholar
• Soneji S, Barrington-Trimis JL, Wills TA, et al. Association between initial use of e-cigarettes and subsequent cigarette smoking among adolescents and young adults: a systematic review and meta-analysis. JAMA Pediatr. 2017;171(8):788–797.
   PubMed Web of Science ®Google Scholar
• Lim CCW, Sun T, Leung J, et al. Prevalence of adolescent cannabis vaping: a systematic review and meta-analysis of US and Canadian studies. JAMA Pediatr. 2022;176(1):42–51.
   PubMed Web of Science ®Google Scholar
• Gentzke AS, Wang TW, Cornelius M, et al. Tobacco product use and associated factors among Middle and high school students — national youth tobacco survey, United States, 2021. MMWR Surveill Summ. 2022;71(5):1–29.
   PubMed Web of Science ®Google Scholar
• Center for Behavioral Health Statistics and Quality. 2020. 2019 National survey on drug use and health: methodological summary and definitions. Rockville (MD): Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/.
   Google Scholar
• Donovan JE. Estimated blood alcohol concentrations for child and adolescent drinking and their implications for screening instruments. Pediatrics. 2009;123(6):e975–e981.
   PubMed Web of Science ®Google Scholar
• Report to Congress on the Prevention and Reduction of Underage Drinking 2020 | SAMHSA Publications and Digital Products. [cited 2021 Dec 17]. https://store.samhsa.gov/product/report-to-congress-prevention-underage-drinking/PEP21-03-11-002.
   Google Scholar
• Pearson MR. Use of alcohol protective behavioral strategies among college students: a critical review. Clin Psychol Rev. 2013;33(8):1025–1040.
   PubMed Web of Science ®Google Scholar
• Friedman J, Godvin M, Shover CL, et al. Trends in drug overdose deaths among US adolescents, January 2010 to June 2021. JAMA. 2022;327(14):1398–1400.
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Gryczynski J, O’Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am J Public Health. 2013;103(5):917–922.
   PubMed Web of Science ®Google Scholar
• Society for Adolescent Health and Medicine. Medication for adolescents and young adults with opioid use disorder. J Adolesc Health off Publ Soc Adolesc Med. 2021;68(3):632–636.
   PubMed Web of Science ®Google Scholar
• Robinson CA, Wilson JD. Management of opioid misuse and opioid use disorders among youth. Pediatrics. 2020;145(Suppl_2):S153–S164.
   PubMedGoogle Scholar
• Frank D, Mateu-Gelabert P, Guarino H, et al. High risk and little knowledge: Overdose experiences and knowledge among young adult nonmedical prescription opioid users. Int J Drug Policy. 2015;26(1):84–91.
   PubMed Web of Science ®Google Scholar
• Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
   PubMed Web of Science ®Google Scholar
• Bagley SM, Peterson J, Cheng DM, et al. Overdose education and naloxone rescue kits for family members of opioid users: characteristics, motivations and naloxone use. Subst Abuse. 2015;36(2):149–154.
   PubMed Web of Science ®Google Scholar
• Noblit S. Naloxone access: summary of state laws. [updated 2020]:174.
   Google Scholar
• Bozinoff N, Small W, Long C, et al. Still “at risk”: an examination of how street-involved young people understand, experience, and engage with “harm reduction” in vancouver’s inner city. Int J Drug Policy. 2017;45:33–39.
   PubMed Web of Science ®Google Scholar
• Never Use Alone – Meeting people where they are, on the other end of the line, one human connection at a time. [cited 2021 Nov 26]. https://neverusealone.com/.
   Google Scholar
• Survival strategies while using drugs alone from people who use drugs. Vital Strategies. [cited 2021 Dec 2]. https://www.vitalstrategies.org/resources/pwudproviderguide/.
   Google Scholar
• Chan CA, Canver B, McNeil R, et al. Harm reduction in health care settings. Med Clin North Am. 2022;106(1):201–217.
   PubMed Web of Science ®Google Scholar
• Krieger MS, Goedel WC, Buxton JA, et al. Use of rapid fentanyl test strips among young adults who use drugs. Int J Drug Policy. 2018;61:52–58.
   PubMed Web of Science ®Google Scholar
• Bergh MSS, Øiestad ÅML, Baumann MH, et al. Selectivity and sensitivity of urine fentanyl test strips to detect fentanyl analogues in illicit drugs. Int J Drug Policy. 2021;90:103065.
   PubMed Web of Science ®Google Scholar
• Davis CS, Lieberman AJ, O’Kelley-Bangsberg M. Legality of drug checking equipment in the United States: a systematic legal analysis. Drug Alcohol Depend. 2022;234:109425.
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med. 2018;169(3):137–145.
   PubMed Web of Science ®Google Scholar
• COMMITTEE ON SUBSTANCE USE AND PREVENTION, Ryan SA, Gonzalez PK, et al. Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics. 2016;138(3):e20161893.
   PubMed Web of Science ®Google Scholar
• Kampman K ,Jarvis M. American Society of Addiction Medicine (ASAM) National practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9:358–367.
   PubMed Web of Science ®Google Scholar
• Opioid Use Disorder Treatment for Youth. [cited 2021 Dec 23]. https://www.aacap.org/aacap/Policy_Statements/2020/Opioid_Use_Disorder_Treatment_Youth.aspx
   Google Scholar
• Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300(17):2003–11.
   PubMed Web of Science ®Google Scholar
• Meade CS, Weiss RD, Fitzmaurice GM, et al. HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multi-site study. J Acquir Immune Defic Syndr 1999. 2010;55(1):65–72.
   PubMed Web of Science ®Google Scholar
• Marsch LA, Moore SK, Borodovsky JT, et al. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction. 2016;111(8):1406–1415.
   PubMed Web of Science ®Google Scholar
• Baldwin P, Shrestha R, Potrepka J, et al. The age of initiation of drug use and sexual behavior may influence subsequent HIV risk behavior: a systematic review. ISRN Aids. 2013;2013:976035–976017.
   PubMedGoogle Scholar
• Golub ET, Strathdee SA, Bailey SL, et al. Distributive syringe sharing among young adult injection drug users in five U.S. cities. Drug Alcohol Depend. 2007;91:S30–S38.
   PubMed Web of Science ®Google Scholar
• Silva K, Schrager SM, Kecojevic A, et al. Factors associated with history of non-fatal overdose among young nonmedical users of prescription drugs. Drug Alcohol Depend. 2013;128(1–2):104–110.
   PubMed Web of Science ®Google Scholar
• Cedarbaum ER, Banta-Green CJ. Health behaviors of young adult heroin injectors in the seattle area. Drug Alcohol Depend. 2016;158:102–109.
   PubMed Web of Science ®Google Scholar
• Taylor JL, Johnson S, Cruz R, et al. Integrating harm reduction into outpatient opioid use disorder treatment settings: harm reduction in outpatient addiction treatment. J Gen Intern Med. 2021;36(12):3810–3819.
   PubMed Web of Science ®Google Scholar
• Mateu-Gelabert P, Guarino H, Jessell L, et al. Injection and sexual HIV/HCV risk behaviors associated with nonmedical use of prescription opioids among young adults in New York City. J Subst Abuse Treat. 2015;48(1):13–20.
   PubMed Web of Science ®Google Scholar
• Syringe Access in Your State. National harm reduction coalition. [cited 2022 Apr 12]. https://harmreduction.org/issues/syringe-access/landscape-report/state-by-state/
   Google Scholar
• Lieberman A, Davis C. Harm reduction laws in the United States. Network for Public Health Law. [cited 2022 Apr 12]. https://www.networkforphl.org/resources/harm-reduction-laws-in-the-united-states/
   Google Scholar
• Bushnell GA, Crystal S, Olfson M. Prescription benzodiazepine use in privately insured U.S. children and adolescents. Am J Prev Med. 2019;57(6):775–785.
   PubMed Web of Science ®Google Scholar
• Benzodiazepines revisited—will we ever learn? – Lader – 2011 – Addiction – Wiley Online Library. [cited 2021 Dec 7]. 10.1111/j.1360-0443.2011.03563.x.
   Google Scholar
• Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv. 2019;70(2):97–106.
   PubMed Web of Science ®Google Scholar
• McCabe SE, West BT, Veliz P, et al. Trends in medical and nonmedical use of prescription opioids among US adolescents: 1976–2015. Pediatrics. 2017;139(4):e20162387.
   PubMed Web of Science ®Google Scholar
• Research C for DE and FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. FDA. [updated 2020 Oct 2; cited 2021 Dec 7]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class.
   Google Scholar
• Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med. 2015;49(4):493–501.
   PubMed Web of Science ®Google Scholar
• Park TW, Saitz R, Ganoczy D, et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698.
   PubMed Web of Science ®Google Scholar
• Bouvier BA, Waye KM, Elston B, et al. Prevalence and correlates of benzodiazepine use and misuse among young adults who use prescription opioids non-medically. Drug Alcohol Depend. 2018;183:73–77.
   PubMed Web of Science ®Google Scholar
• DEA issues public safety alert on sharp increase in fake prescription pills containing fentanyl and meth. [cited 2021 Dec 6]. https://www.dea.gov/press-releases/2021/09/27/dea-issues-public-safety-alert.
   Google Scholar
• Peng L, Morford KL, Levander XA. Benzodiazepines and related sedatives. Med Clin North Am. 2022;106(1):113–129.
   PubMed Web of Science ®Google Scholar
• Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376(12):1147–1157.
   PubMed Web of Science ®Google Scholar
• benzo.org.uk: benzodiazepines: how they work & how to withdraw, Prof C H Ashton DM, FRCP; 2002. [cited 2021 Dec 7]. https://www.benzo.org.uk/manual/index.htm.
   Google Scholar
• Darker CD, Sweeney BP, Barry JM, et al. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev. 2015;(5):CD009652.
   Google Scholar
• Roehler DR, Olsen EO, Mustaquim D, et al. Suspected nonfatal drug-related overdoses among youth in the US: 2016–2019. Pediatrics. 2021;147(1):e2020003491.
   PubMed Web of Science ®Google Scholar
• YRBSS Results | YRBSS | Data | Adolescent and School Health | CDC. [updated 2021 Aug 18; cited 2021 Dec 13]. http://www.cdc.gov/healthyyouth/data/yrbs/results.htm
   Google Scholar
• O’Donnell J, Gladden RM, Mattson CL, et al. Vital signs: characteristics of drug overdose deaths involving opioids and stimulants — 24 states and the District Of Columbia, January–June 2019. MMWR Morb Mortal Wkly Rep. 2020;69(35):1189–1197.
   PubMed Web of Science ®Google Scholar
• Drug overdose deaths involving cocaine and psychostimulants with abuse potential — United States, 2003–2017. [cited 2021 Dec 13]. https://www-ncbi-nlm-nih-gov.ezproxy.bu.edu/pmc/articles/PMC6541315/
   Google Scholar
• Vosburg SK, Faraone SV, Newcorn JH, et al. Prescription stimulant nonmedical use among adolescents evaluated for substance use disorder treatment (CHATTM). J Atten Disord. 2021;25(13):1859–1870.
   PubMed Web of Science ®Google Scholar
• Austic EA, Meier EAAFEA. Peak ages of risk for starting nonmedical use of prescription stimulants. Drug Alcohol Depend. 2015;152:224–229.
   PubMed Web of Science ®Google Scholar
• Park JN, Rashidi E, Foti K, et al. Fentanyl and fentanyl analogs in the illicit stimulant supply: results from U.S. drug seizure data, 2011–2016. Drug Alcohol Depend. 2021;218:108416.
   PubMed Web of Science ®Google Scholar
• Hadland SE, Marshall BDL. Rising stimulant overdoses among young people in the United States. Pediatrics. 2021;147(1):e2020031526.
   PubMed Web of Science ®Google Scholar
• Ciccarone D, Shoptaw S. Understanding stimulant use and use disorders in a new era. Med Clin North Am. 2022;106(1):81–97.
   PubMed Web of Science ®Google Scholar
• Stanger C, Lansing AH, Budney AJ. Contingency management approaches for adolescent substance use disorders. Child Adolesc Psychiatr Clin N Am. 2016;25(4):645–659.
   PubMed Web of Science ®Google Scholar
• Ford CA, Millstein SG, Halpern-Felsher BL, et al. Influence of physician confidentiality assurances on adolescents’ willingness to disclose information and seek future health care: a randomized controlled trial. JAMA. 1997;278(12):1029–1034.
   PubMed Web of Science ®Google Scholar
• Maslyanskaya S, Alderman EM. Confidentiality and consent in the care of the adolescent patient. Pediatr Rev. 2019;40(10):508–516.
   PubMed Web of Science ®Google Scholar
• Sanders RA. Adolescent psychosocial, social, and cognitive development. Pediatr Rev. 2013;34(8):354–358. quiz 358–359.
   PubMedGoogle Scholar
• Ryan SA, Kokotailo P, Camenga DR, et al. Alcohol use by youth. Pediatrics. 2019;144(1):e20191357.,
   PubMedGoogle Scholar
• Kerwin ME, Kirby KC, Speziali D, et al. What can parents do? A review of state laws regarding decision making for adolescent drug abuse and mental health treatment. J Child Adolesc Subst Abuse. 2015;24(3):166–176.
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse Treatment. Screening and assessing adolescents for substance use disorders. Treatment improvement protocol (TIP) Series, no. 31. HHS publication no. (SMA) 12-4079. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1998.
   Google Scholar